Memphasys receives A$3.5 million from Peters Investments
Filed with ASX · · 5 pages · English
Summary by 6ix AI
Memphasys Ltd has announced the receipt of funding from Peters Investments to support the demand for its Felix™ product and enhance global sales efforts. The funding, amounting to a significant advance, will be utilized to expand the company's commercial and manufacturing capabilities. Memphasys is optimistic about its commercial pipeline and ongoing regulatory strategies, particularly in the US market.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Memphasys
- Proposed issue of securities - MEM
- Potential Expedited FDA Pathway to US IVF Market
- Change of Director's Interest Notice
- Notification regarding unquoted securities - MEM
- Application for quotation of securities - MEM
Later from Memphasys
- Initial Director's Interest Notice
- Quarterly Activities/Appendix 4C Cash Flow Report
- Notice of Annual General Meeting/Proxy Form
- Consolidation/Split - MEM
Follow Memphasys into a list and get an email when it puts out news.
Follow Memphasys